MWAS Study Clarifies Link Between Alcohol and Health Risks Through Methylation Insights
PILLAR DIAGNOSTIC // WEEK 08
“The apparent conflict in cohort size is resolved by recognizing that the MWAS cohort (13,970 participants) is a subset of the broader TruDiagnostic TruAge test cohort (15,188 participants). Both figures are accurate within their respective scopes, so overall data integrity remains sound.”
Proposed action
Annotate both claims to specify cohort scope differences—clarify that the MWAS analyses used 13,970 participants drawn from the larger 15,188-person TruAge dataset—and update the machine pillar summary to reflect this subset relationship.
THE MECHANICS
Spread & delivery
Mice were treated with 0.8 mg/kg decitabine once daily for 7 days, DNA and CSF cfDNA were extracted using commercial kits, libraries with 50–400 bp inserts were pooled at 10 nM and sequenced 150 bp paired-end on a NovaSeq 6000 at ~4× coverage, and reads were mapped to hg38 and visualized with deepTools.
THE MACHINE
Evidence & systems
Epigenome-wide methylation profiling approaches—from large-scale MWAS and optimized cell-type deconvolution panels to tumor-agnostic deep-learning classifiers of low-input cfDNA—are rapidly advancing to map disease-associated epigenetic signatures, refine analytical pipelines, and enable minimally invasive diagnostics.
THE MAP
Policy & population
—
THE MOOD
Trust & behavior
Widespread anxiety and concern are mounting over escalating depression, teen suicide risk, addiction-related mood disorders, and treatment-resistant headaches, with WHO projecting depression as the leading global health burden by 2030.
